Pathology after eculizumab in dense deposit disease and C3 GN

Journal of the American Society of Nephrology

Volumn 23, Issue 7, 2012, Pages 1229-1237

  Herlitz, Leal C ^a   Bomback, Andrew S ^a   Markowitz, Glen S ^a   Stokes, M Barry ^a   Smith, R Neal ^b   Colvin, Robert B ^b   Appel, Gerald B ^a   D'Agati, Vivette D ^a  

^a NewYork Presbyterian Hospital   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; ECULIZUMAB; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN KAPPA CHAIN;

ADULT; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT COMPONENT C3 GLOMERULONEPHRITIS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DENSE DEPOSIT DISEASE; DRUG EFFECT; DRUG RESPONSE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

EID: 84863512960     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011121186     Document Type: Article

References (17)

1. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC: C3 glomerulopathy: A new classification. Nat Rev Nephrol 6: 494-499, 2010
2. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD: Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4: 22-32, 2009
3. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F: Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193-199, 2007 (Pubitemid 46580528)
4. D'Agati VD, Jennette JC, Silva FG: Non-Neoplastic Kidney Diseases, Washington, DC, American Registry of Pathology, 2005, pp 250-255
5. Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ:Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 75: 952-960, 2009
6. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M: Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 103: 9649-9654, 2006 (Pubitemid 43955879)
7. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF:Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J AmSoc Nephrol 16: 1392-1403, 2005 (Pubitemid 41716523)
8. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ: Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6: 1009-1017, 2011
9. Daha MR: Role of complement in innate immunity and infections. Crit Rev Immunol 30: 47-52, 2010
10. Ross SC, Densen P: Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63: 243-273, 1984 (Pubitemid 14020907)
11. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33: 1389-1401, 1996 (Pubitemid 27196373)
12. Hillmen P, Young NS, Schubert J, Brodsky RA, SociéG, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355: 1233-1243, 2006 (Pubitemid 44427447)
13. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31: E1445-E1460, 2010
14. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz LC, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB: Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748-756, 2012
15. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264, 2007 (Pubitemid 350076509)
16. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD: Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 12: 1482-1492, 2001 (Pubitemid 32666331)
17. Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W: Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85: 553-559, 2010